Primary focal hyperhidrosis: scope of the problem.
Focal hyperhidrosis (HH) can cause debilitating reductions in the physical and emotional quality of life (QOL) of patients, which can result in numerous restrictions of a patient's personal and professional lifestyle and activities. A variety of treatment options are available for primary focal HH, including topical and oral agents, tap water iontophoresis (TWI), botulinum toxin type A (BTX-A), and surgery. Studies evaluating BTX-A (Botox) treatment for palmar, plantar, and facial HH reveal that BTX-A provides effective treatment of primary focal HH, with a reasonable duration of effect, and has a good safety profile. Physicians should understand the impact of focal HH and the need to stay abreast of the available treatment options to provide the best care for patients.
Glaser
Dee Anna
DA
Department of Dermatology, Saint Louis University, Missouri, USA.
Hebert
Adelaide A
AA
Pariser
David M
DM
Solish
Nowell
N
D051520:Antiperspirants / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D006801:Humans; D006945:Hyperhidrosis / Q000209:etiology / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D007478:Iontophoresis / Q000379:methods; D011788:Quality of Life; D013562:Sympathectomy
D051520:Antiperspirants; D018680:Cholinergic Antagonists; D019274:Botulinum Toxins, Type A